{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:13:03Z","timestamp":1792512783057,"version":"4.5.0"},"reference-count":56,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2023.14204","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T11:55:11Z","timestamp":1703159711000},"source":"Crossref","is-referenced-by-count":6,"title":["miRNAs as predictive biomarkers of response to treatment in pediatric patients with acute lymphoblastic leukemia"],"prefix":"10.3892","volume":"27","author":[{"given":"Eleni","family":"Tsotridou","sequence":"first","affiliation":[{"name":"Children and Adolescent Hematology\u2011Oncology Unit, 2nd Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki AHEPA University Hospital, Thessaloniki 546 36, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisavet","family":"Georgiou","sequence":"additional","affiliation":[{"name":"Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 541 24, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tragiannidis","sequence":"additional","affiliation":[{"name":"Children and Adolescent Hematology\u2011Oncology Unit, 2nd Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki AHEPA University Hospital, Thessaloniki 546 36, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysostomos","family":"Avgeros","sequence":"additional","affiliation":[{"name":"Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 541 24, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tzimagiorgis","sequence":"additional","affiliation":[{"name":"Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 541 24, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lambrou","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Hippokration General Hospital, Thessaloniki 546 42, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Papakonstantinou","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Hippokration General Hospital, Thessaloniki 546 42, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assimina","family":"Galli\u2011Tsinopoulou","sequence":"additional","affiliation":[{"name":"Children and Adolescent Hematology\u2011Oncology Unit, 2nd Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki AHEPA University Hospital, Thessaloniki 546 36, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouel","family":"Hatzipantelis","sequence":"additional","affiliation":[{"name":"Children and Adolescent Hematology\u2011Oncology Unit, 2nd Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki AHEPA University Hospital, Thessaloniki 546 36, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"key20240125115037_b1-ol-27-2-14204","volume-title":"SEER Cancer Statistics Review, 1975\u20132018","author":"Howlader","year":"2011"},{"key":"key20240125115037_b2-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20240125115037_b3-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: An update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20240125115037_b4-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2021.03.034","article-title":"Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: Combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials","volume":"151","author":"Eckert","year":"2021","journal-title":"Eur J Cancer"},{"key":"key20240125115037_b5-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"key":"key20240125115037_b6-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2162-3619-3-16","article-title":"Childhood B-acute lymphoblastic leukemia: A genetic update","volume":"3","author":"Woo","year":"2014","journal-title":"Exp Hematol Oncol"},{"key":"key20240125115037_b7-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs-microRNAs with a role in cancer","volume":"6","author":"Esquela-Kerscher","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"key20240125115037_b8-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2172-15-14","article-title":"MicroRNAs in hematopoietic development","volume":"15","author":"Montagner","year":"2014","journal-title":"BMC Immunol"},{"key":"key20240125115037_b9-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.3390\/ijms19092688","article-title":"MiRNA dysregulation in childhood hematological cancer","volume":"19","author":"Carvalho de Oliveira","year":"2018","journal-title":"Int J Mol Sci"},{"key":"key20240125115037_b10-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2217\/epi-2019-0154","article-title":"MiRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review","volume":"12","author":"Gutierrez-Camino","year":"2019","journal-title":"Epigenomics"},{"key":"key20240125115037_b11-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"348","DOI":"10.5306\/wjco.v11.i6.348","article-title":"Role of microRNA dysregulation in childhood acute leukemias: Diagnostics, monitoring and therapeutics: A comprehensive review","volume":"11","author":"Szczepanek","year":"2020","journal-title":"World J Clin Oncol"},{"key":"key20240125115037_b12-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"3207328","DOI":"10.1155\/2021\/3207328","article-title":"Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and prednisolone on childhood acute lymphoblastic leukemia","volume":"2021","author":"Durmaz","year":"2021","journal-title":"Biomed Res Int"},{"key":"key20240125115037_b13-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1200\/JCO.2013.48.6522","article-title":"Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002","volume":"32","author":"Stary","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20240125115037_b14-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"key":"key20240125115037_b15-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s12859-019-3105-x","article-title":"MIENTURNET: An interactive web tool for microRNA-target enrichment and network-based analysis","volume":"20","author":"Licursi","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"key20240125115037_b16-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"D163","DOI":"10.1093\/nar\/gkq1107","article-title":"miRTarBase: A database curates experimentally validated microRNA-target interactions","volume":"39","author":"Hsu","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"(D1)","key":"key20240125115037_b17-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"D687","DOI":"10.1093\/nar\/gkab1028","article-title":"The reactome pathway knowledgebase 2022","volume":"50","author":"Gillespie","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"key20240125115037_b18-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1055\/s-2008-1026781","article-title":"Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)","volume":"199","author":"Riehm","year":"1987","journal-title":"Klin Padiatr"},{"key":"key20240125115037_b19-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1182\/blood.V94.4.1209","article-title":"Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia","volume":"94","author":"D\u00f6rdelmann","year":"1999","journal-title":"Blood"},{"key":"key20240125115037_b20-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1055\/s-0033-1337966","article-title":"Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000","volume":"225","author":"Schrappe","year":"2013","journal-title":"Klin Padiatr"},{"key":"key20240125115037_b21-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3324\/haematol.2011.047613","article-title":"Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: Differential effects in precursor B-cell and T-cell leukemia","volume":"97","author":"Lauten","year":"2012","journal-title":"Haematologica"},{"key":"key20240125115037_b22-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide reductase and cancer: Biological mechanisms and targeted therapies","volume":"34","author":"Aye","year":"2015","journal-title":"Oncogene"},{"key":"key20240125115037_b23-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"e91644","DOI":"10.1371\/journal.pone.0091644","article-title":"The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients","volume":"9","author":"Su","year":"2014","journal-title":"PLoS One"},{"key":"key20240125115037_b24-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"e006","DOI":"10.1621\/nrs.13006","article-title":"Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma","volume":"13","author":"Thomas","year":"2015","journal-title":"Nucl Recept Signal"},{"key":"key20240125115037_b25-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.gendis.2022.11.022","article-title":"Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer","volume":"11","author":"Zuo","year":"2022","journal-title":"Genes Dis"},{"key":"key20240125115037_b26-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1093\/hmg\/ddr428","article-title":"A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL","volume":"20","author":"Han","year":"2011","journal-title":"Hum Mol Genet"},{"key":"key20240125115037_b27-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1158\/0008-5472.CAN-10-3430","article-title":"6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1","volume":"71","author":"Yuan","year":"2011","journal-title":"Cancer Res"},{"key":"key20240125115037_b28-ol-27-2-14204","first-page":"148","article-title":"Methionine aminopeptidase 2 and cancer","volume":"1765","author":"Selvakumar","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"key20240125115037_b29-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ccell.2018.10.004","article-title":"A CHAF1B-Dependent molecular switch in hematopoiesis and leukemia pathogenesis","volume":"34","author":"Volk","year":"2018","journal-title":"Cancer Cell"},{"key":"key20240125115037_b30-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"7428","DOI":"10.1002\/jcb.28017","article-title":"Dysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia","volume":"120","author":"El-Khazragy","year":"2019","journal-title":"J Cell Biochem"},{"key":"key20240125115037_b31-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/bjc.2017.256","article-title":"MiR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment","volume":"117","author":"Piatopoulou","year":"2017","journal-title":"Br J Cancer"},{"key":"key20240125115037_b32-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/leu.2008.286","article-title":"Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia","volume":"23","author":"Schotte","year":"2009","journal-title":"Leukemia"},{"key":"key20240125115037_b33-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1073\/pnas.1200677109","article-title":"Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A","volume":"109","author":"Chaudhuri","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240125115037_b34-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1074\/jbc.M111.285718","article-title":"miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells","volume":"287","author":"Willimott","year":"2012","journal-title":"J Biol Chem"},{"key":"key20240125115037_b35-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1038\/bjc.2013.562","article-title":"MicroRNA-100\/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R\/mTOR signalling pathways","volume":"109","author":"Li","year":"2013","journal-title":"Br J Cancer"},{"key":"key20240125115037_b36-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1475-2867-13-110","article-title":"MiR-99a may serve as a potential oncogene in pediatric myeloid leukemia","volume":"13","author":"Zhang","year":"2013","journal-title":"Cancer Cell Int"},{"key":"key20240125115037_b37-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3324\/haematol.2010.026138","article-title":"MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia","volume":"96","author":"Schotte","year":"2011","journal-title":"Haematologica"},{"key":"key20240125115037_b38-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.leukres.2013.06.027","article-title":"MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia","volume":"37","author":"Akbari Moqadam","year":"2013","journal-title":"Leuk Res"},{"key":"key20240125115037_b39-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"e7826","DOI":"10.1371\/journal.pone.0007826","article-title":"MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia","volume":"4","author":"Zhang","year":"2009","journal-title":"PLoS One"},{"key":"key20240125115037_b40-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/gcc.22334","article-title":"miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia","volume":"55","author":"Avigad","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"key20240125115037_b41-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"e2371","DOI":"10.1038\/cddis.2016.256","article-title":"miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways","volume":"7","author":"Fang","year":"2016","journal-title":"Cell Death Dis"},{"key":"key20240125115037_b42-ol-27-2-14204","first-page":"376","article-title":"Investigating the inhibitory effect of miR-34a, miR-449a, miR-1827, and miR-106b on target genes including NOTCH1, c-Myc, and CCND1 in human T cell acute lymphoblastic leukemia clinical samples and cell line","volume":"23","author":"Naderi","year":"2020","journal-title":"Iran J Basic Med Sci"},{"key":"key20240125115037_b43-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"48412","DOI":"10.18632\/oncotarget.10270","article-title":"MicroRNA-106b ~ 25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia","volume":"7","author":"Verboon","year":"2016","journal-title":"Oncotarget"},{"key":"key20240125115037_b44-ol-27-2-14204","first-page":"178","article-title":"Association of miRNAs expression profiles with prognosis and relapse in childhood acute lymphoblastic leukemia","volume":"32","author":"Xu","year":"2011","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"key20240125115037_b45-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.12659\/MSM.911002","article-title":"Knockdown of MON1B exerts anti-tumor effects in colon cancer in vitro","volume":"24","author":"Jiang","year":"2018","journal-title":"Med Sci Monit"},{"key":"key20240125115037_b46-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/sj.leu.2401705","article-title":"Transcription factor NF-\u03baB is constitutively activated in acute lymphoblastic leukemia cells","volume":"14","author":"Kordes","year":"2000","journal-title":"Leukemia"},{"key":"key20240125115037_b47-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1182\/bloodadvances.2019001307","article-title":"Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"4","author":"Ueno","year":"2020","journal-title":"Blood Adv"},{"key":"key20240125115037_b48-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12885-020-6599-8","article-title":"Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles","volume":"20","author":"Oh","year":"2020","journal-title":"BMC Cancer"},{"key":"key20240125115037_b49-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.3390\/cancers14205127","article-title":"Association between dysfunction of the nucleolar stress response and multidrug resistance in pediatric acute lymphoblastic leukemia","volume":"14","author":"Nakagawa","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20240125115037_b50-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/iub.427","article-title":"miR-210: More than a silent player in hypoxia","volume":"63","author":"Devlin","year":"2011","journal-title":"IUBMB Life"},{"key":"key20240125115037_b51-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.4161\/cc.9.6.11006","article-title":"MicroRNA-210: A unique and pleiotropic hypoxamir","volume":"9","author":"Chan","year":"2010","journal-title":"Cell Cycle"},{"key":"key20240125115037_b52-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/cas.12370","article-title":"Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia","volume":"105","author":"Mei","year":"2014","journal-title":"Cancer Sci"},{"key":"key20240125115037_b53-ol-27-2-14204","first-page":"8072","article-title":"Low miR-210 and CASP8AP2 expression is associated with a poor outcome in pediatric acute lymphoblastic leukemia","volume":"14","author":"Mei","year":"2017","journal-title":"Oncol Lett"},{"key":"key20240125115037_b54-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s12935-022-02833-2","article-title":"Emerging roles and mechanisms of miR-206 in human disorders: A comprehensive review","volume":"22","author":"Khalilian","year":"2022","journal-title":"Cancer Cell Int"},{"key":"key20240125115037_b55-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3727\/096504019X15555388198071","article-title":"NET1 enhances proliferation and chemoresistance in acute lymphoblastic leukemia cells","volume":"27","author":"Sun","year":"2019","journal-title":"Oncol Res"},{"key":"key20240125115037_b56-ol-27-2-14204","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3390\/cancers13081847","article-title":"Minimal residual disease in acute lymphoblastic leukemia: Current practice and future directions","volume":"13","author":"Contreras Yametti","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T09:55:36Z","timestamp":1706176536000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2023.14204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2023.14204","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"article-number":"71"}}